CC BY-NC-ND 4.0 · Rev Bras Ortop (Sao Paulo) 2023; 58(03): 378-387
DOI: 10.1055/s-0042-1748947
Revisão Sistemática e Metanálise
Quadril

Eficácia do ibuprofeno após artroplastia total de quadril para prevenção de ossificação heterotópica: Revisão sistemática e metanálise[*]

Article in several languages: português | English
1   Departamento de Cirurgia Ortopédica, Dow International Medical College, Karachi, Paquistão
,
1   Departamento de Cirurgia Ortopédica, Dow International Medical College, Karachi, Paquistão
,
1   Departamento de Cirurgia Ortopédica, Dow International Medical College, Karachi, Paquistão
,
2   Departamento de Cirurgia Ortopédica, Dr. Ruth K. M. Pfau Civil Hospital, Karachi, Paquistão
,
1   Departamento de Cirurgia Ortopédica, Dow International Medical College, Karachi, Paquistão
› Author Affiliations
Suporte Financeiro Este estudo não recebeu nenhum auxílio ou suporte financeiro.

Resumo

O objetivo deste estudo foi realizar uma revisão sistemática e metanálise de estudos clínicos randomizados (ECRs) relevantes para determinar o papel do ibuprofeno, sua dose ideal, e a duração do tratamento na prevenção de ossificação heterotópica (OH) após a artroplastia total primária do quadril (ATQ). Uma pesquisa bibliográfica foi feita nos bancos de dados PubMed/MEDLINE e Cochrane Library para a obtenção de ECRs que comparassem o uso de ibuprofeno e de placebo como profilaxia para OH em pacientes submetidos à ATQ. Os principais desfechos deste estudo foram ocorrência geral de OH, classificação de Brooker da OH, e complicações gastrintestinais. No total, 27 artigos foram identificados nos bancos de dados e 4 estudos, com 1.153 pacientes, foram incluídos na análise final. Em comparação ao placebo, o uso de ibuprofeno reduziu a incidência de OH aos 3 e 12 meses de acompanhamento e a incidência de OH Brooker II e III (p < 0,05). No entanto, não houve diferença significativa entre os grupos que receberam ibuprofeno e placebo em termos de interrupção do tratamento devido a complicações gastrintestinais ou da incidência de OH Brooker I e IV (p > 0,05). Os dados existentes indicam que o ibuprofeno é seguro e eficaz na redução da incidência total de OH e de OH Brooker II e III durante o acompanhamento. No entanto, as conclusões são limitadas devido ao pequeno número de estudos; logo, mais estudos clínicos de alta qualidade são necessários para o desenvolvimento de diretrizes em relação à dose e duração ideal da terapia.

* Estudo desenvolvido no Departamento de Cirurgia Ortopédica, Dow International Medical College, Karachi, Paquistão




Publication History

Received: 01 September 2021

Accepted: 14 March 2022

Article published online:
27 June 2022

© 2022. Sociedade Brasileira de Ortopedia e Traumatologia. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commecial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/)

Thieme Revinter Publicações Ltda.
Rua do Matoso 170, Rio de Janeiro, RJ, CEP 20270-135, Brazil

 
  • Referências

  • 1 Varacallo M, Chakravarty R, Denehy K, Star A. Joint perception and patient perceived satisfaction after total hip and knee arthroplasty in the American population. J Orthop 2018; 15 (02) 495-499
  • 2 Hansson S, Bülow E, Garland A, Kärrholm J, Rogmark C. More hip complications after total hip arthroplasty than after hemi-arthroplasty as hip fracture treatment: analysis of 5,815 matched pairs in the Swedish Hip Arthroplasty Register. Acta Orthop 2020; 91 (02) 133-138
  • 3 Healy WL, Iorio R, Clair AJ, Pellegrini VD, Della Valle CJ, Berend KR. Complications of Total Hip Arthroplasty: Standardized List, Definitions, and Stratification Developed by The Hip Society. Clin Orthop Relat Res 2016; 474 (02) 357-364
  • 4 Rosteius T, Rausch V, Pätzholz S. et al. Incidence and risk factors for heterotopic ossification following periprosthetic joint infection of the hip. Arch Orthop Trauma Surg 2019; 139 (09) 1307-1314
  • 5 Brooker AF, Bowerman JW, Robinson RA, Riley Jr LHJ. Ectopic ossification following total hip replacement. Incidence and a method of classification. J Bone Joint Surg Am 1973; 55 (08) 1629-1632
  • 6 Zhu Y, Zhang F, Chen W, Zhang Q, Liu S, Zhang Y. Incidence and risk factors for heterotopic ossification after total hip arthroplasty: a meta-analysis. Arch Orthop Trauma Surg 2015; 135 (09) 1307-1314
  • 7 Manrique J, Alijanipour P, Heller S, Dove M, Parvizi J. Increased Risk of Heterotopic Ossification Following Revision Hip Arthroplasty for Periprosthetic Joint Infection. Arch Bone Jt Surg 2018; 6 (06) 486-491
  • 8 Eggli S, Woo A. Risk factors for heterotopic ossification in total hip arthroplasty. Arch Orthop Trauma Surg 2001; 121 (09) 531-535
  • 9 Rüdiger HA, Dittrich M, Robinson J. et al. The Impact of Heterotopic Ossification on Self-Reported Outcomes After Total Hip Arthroplasty Using the Direct Anterior Approach. J Bone Joint Surg Am 2020; 102 (Suppl. 02) 91-98
  • 10 van Erp JHJ, Massier JRA, Truijen S, Bekkers JEJ, Snijders TE, de Gast A. Heterotopic ossification in primary total hip arthroplasty using the posterolateral compared to the direct lateral approach. Arch Orthop Trauma Surg 2021; 141 (07) 1253-1259
  • 11 Shapira J, Yelton MJ, Chen JW. et al. Efficacy of NSAIDs versus radiotherapy for heterotopic ossification prophylaxis following total hip arthroplasty in high-risk patients: a systematic review and meta-analysis. Hip Int 2021; 1120700021991115
  • 12 Rosenberg DM, Onderdonk B, Majeed NK. et al. Radiation-Induced Sarcoma After Heterotopic Ossification Prophylaxis: A Case Report. JBJS Case Connect 2019; 9 (04) e0146
  • 13 Strauss JB, Chen SS, Shah AP, Coon AB, Dickler A. Cost of radiotherapy versus NSAID administration for prevention of heterotopic ossification after total hip arthroplasty. Int J Radiat Oncol Biol Phys 2008; 71 (05) 1460-1464
  • 14 Kan SL, Yang B, Ning GZ. et al. Nonsteroidal Anti-inflammatory Drugs as Prophylaxis for Heterotopic Ossification after Total Hip Arthroplasty: A Systematic Review and Meta-Analysis. Medicine (Baltimore) 2015; 94 (18) e828
  • 15 Moher D, Liberati A, Tetzlaff J, Altman DG. PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ 2009; 339: b2535
  • 16 Higgins JP, Altman DG, Gøtzsche PC. et al; Cochrane Bias Methods Group, Cochrane Statistical Methods Group. The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. BMJ 2011; 343: d5928
  • 17 DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986; 7 (03) 177-188
  • 18 Higgins JPT, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003; 327 (7414): 557-560
  • 19 Fransen M, Anderson C, Douglas J. et al; HIPAID Collaborative Group. Safety and efficacy of routine postoperative ibuprofen for pain and disability related to ectopic bone formation after hip replacement surgery (HIPAID): randomised controlled trial. BMJ 2006; 333 (7567): 519
  • 20 Persson PE, Sodemann B, Nilsson OS. Preventive effects of ibuprofen on periarticular heterotopic ossification after total hip arthroplasty. A randomized double-blind prospective study of treatment time. Acta Orthop Scand 1998; 69 (02) 111-115
  • 21 Ahrengart L, Blomgren G, Törnkvist H. Short-term ibuprofen to prevent ossification after hip arthroplasty. No effects in a prospective randomized study of 47 arthrosis cases. Acta Orthop Scand 1994; 65 (02) 139-141
  • 22 Elmstedt E, Lindholm TS, Nilsson OS, Törnkvist H. Effect of ibuprofen on heterotopic ossification after hip replacement. Acta Orthop Scand 1985; 56 (01) 25-27
  • 23 Sterne JA, Sutton AJ, Ioannidis JP. et al. Recommendations for examining and interpreting funnel plot asymmetry in meta-analyses of randomised controlled trials. BMJ 2011; 343: d4002
  • 24 Nauth A, Giles E, Potter BK. et al. Heterotopic ossification in orthopaedic trauma. J Orthop Trauma 2012; 26 (12) 684-688
  • 25 Meyers C, Lisiecki J, Miller S. et al. Heterotopic Ossification: A Comprehensive Review. JBMR Plus 2019; 3 (04) e10172
  • 26 Firoozabadi R, Alton T, Sagi HC. Heterotopic Ossification in Acetabular Fracture Surgery. J Am Acad Orthop Surg 2017; 25 (02) 117-124
  • 27 Gebuhr P, Soelberg M, Orsnes T, Wilbek H. Naproxen prevention of heterotopic ossification after hip arthroplasty. A prospective control study of 55 patients. Acta Orthop Scand 1991; 62 (03) 226-229
  • 28 Wahlström O, Risto O, Djerf K, Hammerby S. Heterotopic bone formation prevented by diclofenac. Prospective study of 100 hip arthroplasties. Acta Orthop Scand 1991; 62 (05) 419-421
  • 29 Grohs JG, Schmidt M, Wanivenhaus A. Selective COX-2 inhibitor versus indomethacin for the prevention of heterotopic ossification after hip replacement: a double-blind randomized trial of 100 patients with 1-year follow-up. Acta Orthop 2007; 78 (01) 95-98
  • 30 Legenstein R, Bösch P, Ungersböck A. Indomethacin versus meloxicam for prevention of heterotopic ossification after total hip arthroplasty. Arch Orthop Trauma Surg 2003; 123 (2-3): 91-94
  • 31 Sagi HC, Jordan CJ, Barei DP, Serrano-Riera R, Steverson B. Indomethacin prophylaxis for heterotopic ossification after acetabular fracture surgery increases the risk for nonunion of the posterior wall. J Orthop Trauma 2014; 28 (07) 377-383
  • 32 Zhu XT, Chen L, Lin JH. Selective COX-2 inhibitor versus non-selective COX-2 inhibitor for the prevention of heterotopic ossification after total hip arthroplasty: A meta-analysis. Medicine (Baltimore) 2018; 97 (31) e11649
  • 33 Macfarlane RJ, Ng BH, Gamie Z. et al. Pharmacological treatment of heterotopic ossification following hip and acetabular surgery. Expert Opin Pharmacother 2008; 9 (05) 767-786
  • 34 Walker C. Are All Oral COX-2 Selective Inhibitors the Same? A Consideration of Celecoxib, Etoricoxib, and Diclofenac. Int J Rheumatol 2018; 2018: 1302835
  • 35 Sibbald B. Rofecoxib (Vioxx) voluntarily withdrawn from market. CMAJ 2004; 171 (09) 1027-1028
  • 36 Solomon SD, Wittes J, Finn PV. et al; Cross Trial Safety Assessment Group. Cardiovascular risk of celecoxib in 6 randomized placebo-controlled trials: the cross trial safety analysis. Circulation 2008; 117 (16) 2104-2113
  • 37 Hug KT, Alton TB, Gee AO. Classifications in brief: Brooker classification of heterotopic ossification after total hip arthroplasty. Clin Orthop Relat Res 2015; 473 (06) 2154-2157
  • 38 Mary Jiayi T, Linda P, Michael P. et al. Potential discrepancy between plain films and CT scans in Brooker classification of heterotopic ossification. Br J Radiol 2017; 90 (1080): 20170263
  • 39 Nilsdotter A, Bremander A. Measures of hip function and symptoms: Harris Hip Score (HHS), Hip Disability and Osteoarthritis Outcome Score (HOOS), Oxford Hip Score (OHS), Lequesne Index of Severity for Osteoarthritis of the Hip (LISOH), and American Academy of Orthopedic Surgeons (AAOS) Hip and Knee Questionnaire. Arthritis Care Res (Hoboken) 2011; 63 (Suppl. 11) S200-S207